Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression

Kidney International

Volumn 65, Issue 4, 2004, Pages 1492-1498

  Zoccali, Carmine ^a   Benedetto, Francesco A ^b   Mallamaci, Francesca ^b   Tripepi, Giovanni ^b   Giacone, Giuseppe ^b   Stancanelli, Benedetta ^b   Cataliotti, Alessandro ^b   Malatino, Lorenzo S ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b NONE

Author keywords

Cardiovascular risk; Dialysis; Left ventricular hypertrophy and survival

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SMOKING;

EID: 1642545133     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00530.x     Document Type: Article

References (20)

1. SILBERBERG JS, BARRE PE, PRICHARD SS, SNIDERMAN AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
2. FOLEY RN, PARFREY PS, HARNETT JD, et al: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5:2024-2031, 1995
3. ZOCCALI C, BENEDETTO FA, MALLAMACI F, et al: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
4. LONDON GM, PANNIER B, GUERIN AP, et al: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
5. MIDDLETON RJ, PARFREY PS, FOLEY RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12:1079-1084, 2001
6. PARK CW, SHIN YS, KIM CM, et al: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 40:1230-1239, 2002
7. ZOCCALI C, BENEDETTO FA, MALLAMACI F, et al: Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 33:561-566, 2003
8. BLACHER J, DEMUTH K, GUERIN AP, et al: Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 12:248-255, 1999
9. ZOCCALI C, MALLAMACI F, TRIPEPI G, et al: Nor-epinephrine and concentric hypertrophy in patients with end stage renal disease. Hypertension 40:41-46, 2002
10. ZOCCALI C, MALLAMACI F, MAAS R, et al: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339-345, 2002
11. DEVEREUX RB, ROMAN MJ: Hypertensive cardiac hypertrophy: Pathophysiologic and clinical characteristics, in Hypertension: Pathophysiology, Diagnosis and Management (2nd ed), edited by Laragh JH, Brenner BM, New York, Raven Press, Ltd., 1995, pp 409-424
12. FOLEY RN, PARFREY PS, KENT GM, et al: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11:912-916, 2000
13. LEVY D, SALOMON M, D'AGOSTINO RB, et al: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90:1786-1793, 1994
14. VERDECCHIA P, SCHILLACI G, BORGIONI C, et al: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
15. FOLEY RN, PARFREY PS, MORGAN J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
16. FOLEY RN, PARFREY PS, HARNETT JD, et al: Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7:728-736, 1996
17. DE SIMONE G, DEVEREUX RB, DANIELS SR, et al: Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25:1056-1062, 1995
18. ZOCCALI C, MALLAMACI F, TRIPEPI G, et al: Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 17:1751-1758, 1999
19. ZHANG R, CRUMP J, REISIN E: Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Rep 5:301-308, 2003
20. ZOCCALI C, MALLAMACI F, TRIPEPI G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 63(Suppl 85):105-110, 2003